# Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

> **NCT00514046** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Medullary Thyroid Carcinoma
- Multiple Endocrine Neoplasia Type 2A
- Multiple Endocrine Neoplasia Type 2B

## Interventions

- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT00514046
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-20
- **Primary completion:** 2019-12-10
- **Final completion:** 2020-11-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514046, "Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00514046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*